Therapeutic targeting of nuclear receptor corepressor misfolding in acute promyelocytic leukemia cells with genistein

Molecular Cancer Therapeutics

Volumn 6, Issue 8, 2007, Pages 2240-2248

  Ng, Angela Ping Ping ^a   Nin, Dawn Sijin ^a   Fong, Jek Howe ^a   Venkataraman, Divya ^a   Chen, Chien Shing ^b,c,d   Khan, Matiullah ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; CELL NUCLEUS RECEPTOR; CYTOCHROME C; GENISTEIN; RETINOIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MEMBRANE POTENTIAL; CYTOSOL; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 9; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENISTEIN; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEMBRANE POTENTIAL, MITOCHONDRIAL; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PEPTIDE HYDROLASES; PHOSPHOSERINE; PHOSPHOTYROSINE; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, RETINOIC ACID; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 34548079498     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0705     Document Type: Article

References (32)

1. Pandolfi PP, Alcalay M, Fagioli M, et al. Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARα isoforms in acute promyelocytic leukaemia. EMBO J 1992;4:1397-07.
2. Kakizuka A, Miller WH, Jr., Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR with a novel putative transcription factor PML. Cell 1991;66:663-74.
3. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001;20:7140-5.
4. Lengfelder E, Gnad U, Buchner T, Hehlmann R. Treatment of relapsed acute promyelocytic leukemia. Onkologie 2003;26:373-9.
5. Chomienne C, Fenaux P, Degos L. Retinoid differentiation therapy in promyelocytic leukemia. FASEB J 1996;10:1025-30.
6. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A. Reduced retinoic acid sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RAR underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998;91:2634-42.
7. Lin R J, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998;391:811-4.
8. Grignani F, De Matteis S, Nervi C, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998;391:815-8.
9. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-41.
10. Khan MM, Nomura T, Kim H, et al. Role of PML and PML-RARα in Mad-mediated transcriptional repression. Mol Cell 2001;6:1233-43.
11. Khan MM, Nomura T, Chiba T, et al. The fusion on-protein PML-RAR induces endoplasmic reticulum associated degradation of N-CoR and ER stress. J Biol Chem 2004;279:11814-24.
12. Ng APP, Howe FH, Dawn NS, et al. Cleavage of mis-folded nuclear receptor co-repressor (N-CoR) confers resistance to unfolded protein induced-apoptosis. Cancer Res 2006;66:9903-12.
13. Zhou Y, Lee AS. Mechanism for the suppression of the mammalian stress response by Genstein, an anticancer Phytoestrogen from Soy. J Natl Cancer Inst 1998;90:381-8.
14. Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine specific protein kinase. J Biol Chem 1987;262:5592-5.
15. Green NS, Foss TR, Kelly JW. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc Natl Acad Sci U S A 2005;102:14545-50.
16. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991;77:1080-6.
17. Duprez E, Lillehaug JR, Gaub MP, Lanotte M. Differential changes of retinoid-X-receptor (RXRα) and its RARα and PML-RARα partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells. Oncogene 1996;12:2443-50.
18. Shao WL, Benedetti WW, Lamph CN, Miller WHJ. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 1997;89:4282-9.
19. Wong WSF, Leong KP. Tyrosine kinas inhibitors, a new approach to asthma. BBA 2004;1697:53-69.
20. Salvesen GS, Dixit VM. Intracellular signaling by proteolysis. Cell 1997;91:443-58.
21. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
22. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000;14:262-71.
23. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-6.
24. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-67.
25. 3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000;14:431-40.
26. Guo A, Salomoni P, Luo J, et al. The function of PML in P53 dependent apoptosis. Nat Cell Biol 2000;2:730-6.
27. Hayakawa F, Privalsky M. Phosphorylation of PML by mitogen activated kinase plays a key role in arsenic trioxide mediated apoptosis. Cancer Cell 2004;3:389-401.
28. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet 1998;20:259-65.
29. Lane AA, Ley TJ. Neutrophil elastase cleaves PML-RAR_and is important for the development of acute promyelocytic leukemia in mice. Cell 2003;115:305-18.
30. Dijsselbloem N, Goriely S, Albarani V, et al. A Critical Role for p53 in the Control of NF-{κ}B-Dependent Gene Expression in TLR4-Stimulated Dendritic Cells Exposed to Genistein. J Immunol 2007;178:5048-57.
31. Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu N, Boone E, Haegeman G. Attenuation of mitogen- and stress-activated protein kinase-1-driven nuclear factor-κB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 2006;66:4852-62.
32. Cohen FE, Kelly JW. Therapeutic approach to protein-mis-folding diseases. Nat Rev Cancer 2003;4:905-9.